Thomas A. Morinelli

Thomas A. Morinelli

Auto-generated profile, based on publicly available information

Thomas A. Morinelli

Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2018 in Nephrology
Verified
Journal Article
Closed access
PDF file
DDDerek A DuBay
Derek A DuBay
ZSZemin Su
Zemin Su
TMThomas A Morinelli
Thomas A Morinelli
PBPrabhakar Baliga
Prabhakar Baliga
VRVinayak Rohan
Vinayak Rohan
DTDavid J Taber
David J Taber

12 March 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
EWErin R. Weeda
Erin R. Weeda
ZSZemin Su
Zemin Su
DTDavid J. Taber
David J. Taber
JBJohn Bian
John Bian
TMThomas A. Morinelli
Thomas A. Morinelli
DDDerek A. DuBay
Derek A. DuBay

28 December 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
HKHidenobu Kojima
Hidenobu Kojima
TMThomas A. Morinelli
Thomas A. Morinelli
YWYue Wang
Yue Wang
JCJackson L. Chin
Jackson L. Chin
AMAaron S. Meyer
Aaron S. Meyer
YZYuan Zhai
Yuan Zhai
As important immune regulatory cells, whether innate lymphoid cells (ILCs) are involved in liver transplantation (LT) remains unclear. In a murine orthotopic LT model, we dissected roles of ILCs in liver ischemia-reperfusion injury (IRI). Wild-type (WT) grafts suffered significantly higher IRI in Rag2-γc double knockout (DKO) than Rag2 knockout (KO) recipients, in association with downregulation of group 1 ILCs genes, including interferon gamma. Antibody-mediated ILC depletion or interferon gamma neutralization in Rag2 KO recipients increased, while interferon gamma treatment in DKO recipients reduced, liver graft injuries. At the donor side, grafts from DKO mice or anti-NK1.1-treated WT mice suffered significantly higher IRI, while grafts treated with interferon gamma during cold preservation decreased IRI. Thus, both recipient and donor group 1 ILCs protect liver grafts from IRI. Low-dose interferon gamma upregulated c-FLIP expression in vitro and in vivo and protected hepatocytes from inflammatory cell death. In human liver graft biopsies, single-cell RNA-sequencing analysis revealed group 1 ILCs produce interferon gamma. The c-FLIP levels were positively correlated with interferon gamma in pretransplant biopsies. Grafts with higher c-FLIP were associated with lower caspase-8 activation, IRI gradings, and frequency of early allograft dysfunction post-LT. Our study reveals a novel interferon gamma-mediated cytoprotective role of group 1 ILCs in LT.

3 September 2018 in Transplant International
Verified
Journal Article
Closed access
PDF file
DTDavid J. Taber
David J. Taber
ZSZemin Su
Zemin Su
JFJames N. Fleming
James N. Fleming
NPNicole A. Pilch
Nicole A. Pilch
TMThomas Morinelli
Thomas Morinelli
DDDerek Dubay
Derek Dubay
An improved understanding of the impact of clinical surrogates on disparities in African‐American (AA) kidney transplantation (KTX) is needed. We conducted a 10‐year retrospective longitudinal cohort study of electronically abstracted clinical data assessing the impact of surrogates on disparities in KTX. Clinical surrogates were assessed by posttransplant year (1, 2, 3 or 4) and defined as acute rejection (Banff ≥1A), mean SBP >140 mmHg, tacrolimus variability (CV) >40%, mean glucose >160 mg/dl and mean hemoglobin <10 g/dl. We utilized landmark methodology to minimize immortal time bias and logistic and survival regression to assess outcomes; 1610 KTX were assessed (54.2% AAs), with 1000, 468, 368 and 303 included in the year 1, 2, 3 and 4 complete case analyses, respectively. AAs had significantly higher odds of developing a clinical surrogate, which increased in posttransplant years three and four [OR year 1 1.99 (1.38–2.88), year 2 1.77 (1.20–2.62), year 3 2.35 (1.49–3.71), year 4 2.85 (1.72–4.70)]. Adjusting for the five clinical surrogates in survival models explained a significant portion of the higher risks of graft loss in AAs in post‐transplant years three and four. Results suggest focusing efforts on improving late clinical surrogate management within AAs may help mitigate racial disparities in KTX.

4 September 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
DDDerek A. DuBay
Derek A. DuBay
NINataliya V. Ivankova
Nataliya V. Ivankova
IHIvan Herbey
Ivan Herbey
DRDavid T. Redden
David T. Redden
CHCheryl Holt
Cheryl Holt
MMMichelle Y. Martin
Michelle Y. Martin

7 December 2021 in Progress in Transplantation
Verified
Journal Article
Closed access
PDF file
TMThomas A. Morinelli
Thomas A. Morinelli
DTDavid J. Taber
David J. Taber
ZSZemin Su
Zemin Su
JRJames R. Rodrigue
James R. Rodrigue
ZSZachary Sutton
Zachary Sutton
DDDerek A. DuBay
Derek A. DuBay
Introduction: The optimal treatment for end-stage kidney disease is renal transplant. However, only 1 in 5 (21.5%) patients nationwide receiving dialysis are on a transplant waitlist. Factors associated with patients not initiating a transplant evaluation are complex and include patient specific factors such as transplant knowledge and self-efficacy. Research Question: Can a dialysis center-based educational video intervention increase dialysis patients’ transplant knowledge, self-efficacy, and transplant evaluations initiated? Design: Dialysis patients who had not yet completed a transplant evaluation were provided a transplant educational video while receiving hemodialysis. Patients’ transplant knowledge, self-efficacy to initiate an evaluation, and dialysis center rates of transplant referral and evaluation were assessed before and after this intervention. Results: Of 340 patients approached at 14 centers, 252 (74%) completed the intervention. The intervention increased transplant knowledge (Likert scale 1 to 5: 2.53 [0.10] vs 4.62 [0.05], P < .001) and transplant self-efficacy (2.55 [0.10] to 4.33 [0.07], P < .001. The incidence rate per 100 patient years of transplant evaluations increased 85% (IRR 1.85 [95% CI: 1.02, 3.35], P = .0422) following the intervention. The incidence rates of referrals also increased 56% (IRR 1.56 [95% CI: 1.03, 2.37], P = .0352), while there was a nonsignificant 47% increase in incidence rates of waitlist entries (IRR 1.47 [95% CI: 0.45, 4.74], P = .5210). Conclusion: This dialysis center-based video intervention provides promising preliminary evidence to conduct a large-scale randomized controlled trial to test its effectiveness in increasing self-efficacy of dialysis patients to initiate a transplant evaluation.